Table 1.
Species distribution of 54 Trichosporon spp. clinical isolates according to the site of infection or colonization identifiyed by IGS1 rDNA sequencing.
Figure 1.
Median-joining genotypes network of T. asahii, T. faecale and T. coremiiforme based on IGS1 rDNA sequences related to biofilm quantitation.
Dashed square groups the 12 different genotypes (G1 to G12) of T. asahii. Dashed circle groups the 3 different genotypes of T. faecale. Circumference sizes are proportional to the genotype frequencies. Black dots (mv = median vectors) are hypothetical missing intermediates.
Figure 2.
Inter and intra species variation in the biofilm production of 54 Trichosporon spp. clinical isolates and 7 reference strains.
A- 19 isolates from blood identified as T. asahii, T. asteroides, T. coremiiforme and T. dermatis. B- 20 isolates from urine identified as T. asahii. C- 15 isolates from superficial mycosis/skin colonization identified as T. asahii, T. dermatis, T. faecale and T. inkin. D- 7 reference strains from CBS obtained from different sources.
Figure 3.
Scanning electron microscopy of 4 Trichosporon spp. strains grown on catheter surfaces.
A and B: Low biofilm producer T. asahii 05-001 (CV-A570 = 0.287); C and D: Medium biofilm producer T. asahii 18-001 (CV-A570 = 1.557); E and F: High biofilm producer T. asahii 07-001A (CV-A570 = 3.337); and G and H: High biofilm producer T. asteroides 13-001 (CV-A570 = 2.755).
Figure 4.
Comparative analysis of MIC values obtained against planktonic cells of T. asahii (36 isolates) versus non-T. asahii (18) isolates for all antifungals tested.
A- Fluconazole; B- Itraconazole; C- Voriconazole and D- Amphotericin B.
Table 2.
In vitro activity of 4 antifungal drugs against planktonic cells of 54 clinical isolates of Trichosporon spp. according to the isolation site.
Table 3.
In vitro activity of 4 antifungal drugs against biofilm forming cells of 54 clinical isolates of Trichosporon spp.